Piper Sandler starts Tourmaline at overweight, cites upcoming catalysts (TRML)


word m and a made with wood building blocks, stock image

Maksim Labkouski

Piper Sandler has initiated coverage of Tourmaline Bio (NASDAQ:TRML) with an overweight rating, citing its potential to become a “key leader” in the inflammation and immunology space.

The investment bank said it sees the company’s drug candidate TOUR006 as a

Source link

Leave A Reply

Your email address will not be published.